Vlado Perkovic on Additional FLOW, APPLAUSE-IgAN, and CREDENCE Findings

Vlado Perkovic, MBBS, PhD, made headlines earlier in 2024 with the FLOW trial results showing the significant benefits of semaglutide on kidney outcomes in high-risk patients. FLOW was still making waves at ASN Kidney Week in the fall, with a high-impact presentation showing semaglutide reduced risks of major kidney outcomes irrespective of chronic kidney disease severity, and a late-breaking oral session showing the drug significantly reduced the risk of all-cause and cardiovascular death.

Dr. Perkovic contributed to several other Kidney Week presentations, including a few presenting additional results from the APPLAUSE-IgAN study of iptacopan and the CREDENCE trial of canagliflozin.

Nephrology Times spoke with Dr. Perkovic about all three trials following the conference.